A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab

Go down

A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab Empty A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab

Post  Jon Moulton on Mon Apr 27, 2015 12:18 pm

Chu TW, Zhang R, Yang J, Chao MP, Shami PJ, Kopeček J. A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab. Theranostics. 2015;5(8):834-46. doi:10.7150/thno.12040
Jon Moulton
Jon Moulton

Posts : 5721
Join date : 2010-03-12
Age : 57
Location : Philomath, Oregon, USA

http://www.gene-tools.com

Back to top Go down

Back to top


 
Permissions in this forum:
You cannot reply to topics in this forum